Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.
Your search for oral corticosteroids returned 7 results
The Food and Drug Administration (FDA) has granted Fast Track designation to the investigational oral dual inhibitor, ASN002 (Asana BioSciences), for the treatment of moderate-to-severe atopic dermatitis.
“Closer collaboration between dermatologists and oncologists is essential,” write the authors.
The FDA decision to grant Priority Review was based on results from a National Institute of Health (NIH) study which demonstrated a 52% complete response rate and an 85% overall response rate in treatment-naïve SAA patients treated with eltrombopag plus standard IST.
Omega-3 fatty acids contained in fish oil was shown to have a lowering effect on lgE production (the antibodies which fuel asthma), suggesting that omega-3 fatty acids may be utilized to treat asthma patients.
Rheumatoid arthritis (RA) patients have a greater prevalence and severity of periodontitis than the non-arthritis population, according to a new study published in the Korean Journal of Internal Medicine.
Dermatoses in pregnancy provides a challenge to dermatologists when it comes to recommending treatments that are effective yet safe to the fetus.